多药合用对利伐沙班与维生素K拮抗剂治疗静脉血栓栓塞症出血的影响
在EINSTEIN-VTE研究的8246例急性静脉血栓栓塞症患者中,评估多药合用对出血及利伐沙班与依诺肝素/维生素K拮抗剂(VKA)相对差异的影响。随着合并用药数量增加,利伐沙班组临床相关出血发生率从5.7%升至13.3%,依诺肝素/VKA组从9.1%升至11.1%。无合并用药时利伐沙班出血风险低于依诺肝素/VKA(HR 0.6,95%CI 0.4-0.9),≥4种合并用药时风险相似(HR 1.2,95%CI 0.97-1.5,交互作用P=0.002)。
要点
- 随着合并用药数量增加,利伐沙班组临床相关出血发生率从5.7%升至13.3%,依诺肝素/VKA组从9.1%升至11.1%。
- 无合并用药时利伐沙班较依诺肝素/VKA出血风险降低(HR 0.6,95%CI 0.4-0.9),≥4种合并用药时风险相似(HR 1.2,95%CI 0.97-1.5)。
- 使用CYP3A4和/或P-gp抑制剂与未使用相比出血风险约翻倍,利伐沙班与依诺肝素/VKA之间无差异。
核心结论
- 固定剂量利伐沙班与依诺肝素后接剂量调整VKA相比,在合并多药治疗(包括CYP3A4和/或P-gp抑制剂)的VTE患者中未增加出血风险。
- 多药合用及使用CYP3A4和/或P-gp抑制剂所观察到的出血风险增加可能由合并症和虚弱解释,而非药代动力学相互作用。
研究设计与样本
- 基于EINSTEIN-VTE研究纳入的8246例急性VTE患者,评估多药合用对出血及利伐沙班与依诺肝素/VKA相对差异的影响。
- 按基线合并用药数量(无、1-3种、≥4种)及CYP3A4和/或P-gp抑制剂使用情况评估临床相关出血(主要出血和临床相关非主要出血)发生率。
- 采用Cox回归分析评估利伐沙班与依诺肝素/VKA和合并用药间的交互作用,计算交互作用P值。
主要发现
- 随着合并用药数量增加,利伐沙班组临床相关出血发生率从5.7%升至13.3%,依诺肝素/VKA组从9.1%升至11.1%。
- 无合并用药时利伐沙班较依诺肝素/VKA出血风险降低(HR 0.6,95%CI 0.4-0.9)。
- ≥4种合并用药时利伐沙班与依诺肝素/VKA出血风险相似(HR 1.2,95%CI 0.97-1.5,交互作用P=0.002)。
- 使用CYP3A4和/或P-gp抑制剂与未使用相比出血风险约翻倍,利伐沙班与依诺肝素/VKA之间无差异。
临床怎么用
- 作者认为,固定剂量利伐沙班用于合并多药治疗(包括CYP3A4和/或P-gp抑制剂)的VTE患者时,与依诺肝素后接剂量调整VKA相比未增加出血风险。
- 作者认为,多药合用及CYP3A4和/或P-gp抑制剂使用所观察到的出血风险增加可能由合并症和虚弱解释,而非药代动力学相互作用。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Polypharmacy, including use of inhibitors of CYP3A4 and P-glycoprotein (P-gp), is common in patients with venous thromboembolism (VTE) and is associated with increased bleeding. METHODS: In 8246 patients included in the EINSTEIN-VTE studies for acute VTE, we evaluated the effect of polypharmacy on bleeding and on the relative differences between rivaroxaban and enoxaparin/vitamin K antagonist (VKA). We assessed the incidence of clinically relevant bleeding (major and clinically relevant nonmajor bleeding) by number of comedications (none, 1-3, ≥4) at baseline, and by use of CYP3A4 and/or P-gp inhibitors. Interaction between rivaroxaban versus enoxaparin/VKA and comedication was assessed by Cox regression analysis with pinteraction estimates. RESULTS: With increasing number of comedications, the incidence of clinically relevant bleeding rose from 5.7% to 13.3% in rivaroxaban recipients and from 9.1% to 11.1% in enoxaparin/VKA recipients. Whereas rivaroxaban was associated with a reduced bleeding risk compared with enoxaparin/VKA in patients without comedication (hazard ratio [HR] 0.6, 95% confidence interval [CI] 0.4-0.9), the risk was similar in patients with ≥4 comedications (HR 1.2, 95% CI 0.97-1.5, pinteraction .002). Use of CYP3A4 and/or P-gp inhibitors was associated with a doubled bleeding risk compared with no use, without a difference between rivaroxaban and enoxaparin/VKA. CONCLUSION: We conclude that fixed-dose rivaroxaban as compared with enoxaparin followed by dose-adjusted VKA is not associated with an increased bleeding risk in patients with VTE administered polypharmacy in general and CYP3A4 and/or P-gp inhibitors specifically. This implies that the observed increased bleeding risks with polypharmacy and use of CYP3A4 and/or P-gp inhibitors are likely explained by comorbidities and frailty, and not by pharmacokinetic interactions.
引用
- Bistervels IM, Bavalia R, Gebel M, et al. Effect of polypharmacy on bleeding with rivaroxaban versus vitamin K antagonist for treatment of venous thromboembolism. J Thromb Haemost. 2022. PMID: 35253983. doi:10.1111/jth.15692
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。